QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.107.034298v1 72/2/380    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ma, J.-N. Articles by Burstein, E. S. Search for Related Content PubMed PubMed Citation Articles by Ma, J.-N. Articles by Burstein, E. S.

Identification of the Atypical L-Type Ca²⁺ Channel Blocker Diltiazem and Its Metabolites As Ghrelin Receptor Agonists

ACADIA Pharmaceuticals, Inc., San Diego, California

Using a high-throughput functional screen, the atypical L-type Ca²⁺ channel blocker diltiazem was discovered to be an agonist at the human ghrelin (GHSR1a) receptor. In cellular proliferation, Ca²⁺ mobilization, and bioluminescence resonance energy transfer (BRET-2) assays, diltiazem was a partial agonist at GHSR1a receptors, with 50 to 80% relative efficacy compared with the GHSR1a peptide agonist GHRP-6, and high nanomolar to low micromolar potency, depending upon the assay. Seven of the known primary metabolites of diltiazem were synthesized, and three of them (M_A, M₁, and M₂) were more efficacious and/or more potent than diltiazem at GHSR1a receptors, with a rank order of agonist activity of M₂ > M₁ > M_A > diltiazem, whereas M₄ and M₆ metabolites displayed weak agonist activity, and the M₈ and M₉ metabolites were inactive. Binding affinities of diltiazem and these metabolites to GHSR1a receptors followed a similar rank order. In vivo tests showed that diltiazem and M₂ each stimulated growth hormone release in male Sprague-Dawley neonatal rats, although to a lesser degree than GHRP-6. Thus, diltiazem and chemical analogs of diltiazem represent a new class of GHSR1a receptor agonists. The possible contributions of GHSR1a receptor activation to the clinical actions of diltiazem are discussed in the context of the known beneficial cardiovascular effects of ghrelin.

Address correspondence to: Ethan S. Burstein, ACADIA Pharmaceuticals, Inc., 3911 Sorrento Valley Blvd., San Diego, CA 92121. E-mail: eburstein{at}acadia-pharm.com